Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2017Cardiovascular DiabetologyOpen Access

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does dipeptidyl peptidase-4 inhibitor reduce new-onset atrial fibrillation in patients with diabetes taking metformin?

Population

90,880 patients with diabetes taking metformin as first-line therapy from Taiwan's National Health Insurance…

Comparison

Dipeptidyl peptidase-4 inhibitor prescribed as a… vs Other hypoglycemic agents prescribed as a…

Design

Cohort

Follow-up

Over a 3-year period

Authors

CCChia‐Yu ChangYYYung‐Hsin YehYCYi‐Hsin Chan

Discussion

Loading...

Member takes

Overview

May inform second-line DPP4i choice in T2DM on metformin; hypothesis-generating pending RCTs.

Structured PICO

Does dipeptidyl peptidase-4 inhibitor reduce new-onset atrial fibrillation in patients with diabetes taking metformin?

P
Population
90,880 patients with diabetes taking metformin as first-line therapy from Taiwan's National Health Insurance Research Database
I
Intervention
Dipeptidyl peptidase-4 inhibitor (DPP4i) prescribed as a second-line hypoglycemic agent (76% sitagliptin)
C
Comparator
Other hypoglycemic agents prescribed as a second-line drug (81% sulfonylurea)
O
Outcome
New-onset atrial fibrillationhard clinical

In patients with type 2 diabetes on metformin, the addition of a DPP4i as a second-line agent is associated with a significantly lower risk of new-onset atrial fibrillation compared to other second-line agents.

Cite This Study

Chang et al. (2017) studied this question.

synapsesocial.com/papers/6a8415cd7e95b97f4e72f724https://doi.org/10.1186/s12933-017-0640-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antihyperglycemic drugs use and new‐onset atrial fibrillation in elderly patients2017 · 42 citations
  2. 2Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study2016 · 16 citations
  3. 3A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan2016 · 19 citations
  4. 4Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation2017 · 35 citations
  5. 5Impact of Atrial Fibrillation on the Risk of Death1998 · 4,611 citations